Lyell Immunopharma Stock Performance
| LYEL Stock | USD 0.58 0.05 9.43% |
The company secures a Beta (Market Risk) of 1.49, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lyell Immunopharma will likely underperform. Lyell Immunopharma right now secures a risk of 5.41%. Please verify Lyell Immunopharma treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Lyell Immunopharma will be following its current price movements.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Lyell Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent technical and fundamental indicators, Lyell Immunopharma is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors. ...more
1 | After Plunging -37.9 percent in 4 Weeks, Heres Why the Trend Might Reverse for Lyell Immunopharma | 12/31/2024 |
2 | Disposition of 700000 shares by Stephen Hill of Lyell Immunopharma at 5.98 subject to Rule 16b-3 | 01/10/2025 |
3 | Lyell Immunopharma Faces Nasdaq delisting over share price - Investing.com | 01/24/2025 |
4 | BlackRock, Inc. Reduces Stake in Lyell Immunopharma Inc | 02/05/2025 |
5 | Acquisition by Gary Lee of 56250 shares of Lyell Immunopharma at 0.5535 subject to Rule 16b-3 | 02/10/2025 |
6 | Cell Therapy Pioneer Lyell to Showcase Cancer Treatment Breakthroughs at Elite Investor Events - StockTitan | 02/18/2025 |
7 | Lyell Immunopharma, Inc. Sees Large Drop in Short Interest | 03/07/2025 |
8 | Lyell Immunopharmas Global Expansion Strategy Navigating Risks and Challenges - TipRanks | 03/12/2025 |
9 | Lyell Immunopharma Issues Quarterly Earnings Results | 03/14/2025 |
10 | Acquisition by Charles Newton of 200000 shares of Lyell Immunopharma at 0.5581 subject to Rule 16b-3 | 03/17/2025 |
11 | Favourable Signals For Lyell Immunopharma Numerous Insiders Acquired Stock | 03/20/2025 |
12 | Lynn Seely Buys 175,000 Shares of Lyell Immunopharma, Inc. Stock | 03/21/2025 |
| Begin Period Cash Flow | 145.9 M |
Lyell |
Lyell Immunopharma Relative Risk vs. Return Landscape
If you would invest 62.00 in Lyell Immunopharma on December 22, 2024 and sell it today you would lose (4.00) from holding Lyell Immunopharma or give up 6.45% of portfolio value over 90 days. Lyell Immunopharma is currently generating 0.032% in daily expected returns and assumes 5.4133% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Lyell, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lyell Immunopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lyell Immunopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lyell Immunopharma, and traders can use it to determine the average amount a Lyell Immunopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0059
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LYEL |
Estimated Market Risk
| 5.41 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lyell Immunopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lyell Immunopharma by adding Lyell Immunopharma to a well-diversified portfolio.
Lyell Immunopharma Fundamentals Growth
Lyell Stock prices reflect investors' perceptions of the future prospects and financial health of Lyell Immunopharma, and Lyell Immunopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lyell Stock performance.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | (141.33 M) | ||||
| Shares Outstanding | 295.23 M | ||||
| Price To Earning | 3.66 X | ||||
| Price To Book | 0.44 X | ||||
| Price To Sales | 2,800 X | ||||
| Revenue | 61 K | ||||
| Gross Profit | 61 K | ||||
| EBITDA | (3.31 M) | ||||
| Net Income | (342.99 M) | ||||
| Cash And Equivalents | 655.56 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 50.99 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.26 X | ||||
| Book Value Per Share | 1.30 X | ||||
| Cash Flow From Operations | (162.39 M) | ||||
| Earnings Per Share | (1.31) X | ||||
| Market Capitalization | 170.79 M | ||||
| Total Asset | 490.86 M | ||||
| Retained Earnings | (1.35 B) | ||||
| Working Capital | 325.81 M | ||||
About Lyell Immunopharma Performance
By examining Lyell Immunopharma's fundamental ratios, stakeholders can obtain critical insights into Lyell Immunopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Lyell Immunopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.70) | (0.66) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.70) | (0.66) | |
| Return On Equity | (0.90) | (0.85) |
Things to note about Lyell Immunopharma performance evaluation
Checking the ongoing alerts about Lyell Immunopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lyell Immunopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lyell Immunopharma had very high historical volatility over the last 90 days | |
| Lyell Immunopharma has some characteristics of a very speculative penny stock | |
| Lyell Immunopharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 61 K. Net Loss for the year was (342.99 M) with profit before overhead, payroll, taxes, and interest of 61 K. | |
| Lyell Immunopharma currently holds about 655.56 M in cash with (162.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lyell Immunopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Lynn Seely Buys 175,000 Shares of Lyell Immunopharma, Inc. Stock |
- Analyzing Lyell Immunopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lyell Immunopharma's stock is overvalued or undervalued compared to its peers.
- Examining Lyell Immunopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lyell Immunopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lyell Immunopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lyell Immunopharma's stock. These opinions can provide insight into Lyell Immunopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.